Generic Name and Formulations:
Natamycin 5%; oph susp; contains benzalkonium chloride 0.02%.
Alcon Laboratories, Inc.
Indications for NATACYN:
Treatment of fungal blepharitis, conjunctivitis, and keratitis due to susceptible organisms including Fusarium solani keratitis.
Keratitis: initially 1 drop in the conjunctival sac at hourly or two-hourly intervals. May reduce to 1 drop 6–8 times daily after the first 3–4 days. Continue for 14–21 days or until resolution. Reduce dose gradually at 4–7 day intervals to assure replicating organism is eliminated. Blepharitis, conjunctivitis: less frequent initial dosage (4–6 daily applications) may be sufficient.
Reevaluate if no improvement after 7–10 days. Monitor at least twice weekly; discontinue if drug toxicity occurs. Pregnancy (Cat. C). Nursing mothers.
Conjunctival chemosis and hyperemia.
Neurology Advisor Articles
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis
- Early Onset of Efficacy After Erenumab Treatment in Chronic and Episodic Migraines